Cited 15 times in
Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 신혜선 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 전재윤 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2014-12-19T17:07:26Z | - |
dc.date.available | 2014-12-19T17:07:26Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90820 | - |
dc.description.abstract | BACKGROUND AND AIM: Little information is available about the antiviral efficacy of lamivudine (LAM) and entecavir (ETV) in patients with hepatitis B virus (HBV)-related advanced hepatocellular carcinoma (HCC). Thus, we compared the antiviral efficacy of LAM and ETV in these patients. METHODS: The medical records of 134 antiviral therapy-naïve patients with HBV-related advanced HCC (modified Union for International Cancer Control [UICC] Tumor, Nodes, and Metastases [TNM] stages III-IV) treated between January 2005 and September 2009 were reviewed. After HCC diagnosis, 87 (64.9%) and 47 (35.1%) patients received LAM and ETV, respectively. RESULTS: The mean age of patients (115 men, 19 women) was 53 years. Sixty-five (48.5%) and 69 (51.5%) patients had TNM stages III and IV HCC, respectively. Treatment outcomes during follow-up, including virologic, biochemical, and serologic responses and appearance of antiviral resistance, were similar in the LAM and ETV groups (all P>0.05). Multivariate analysis identified Child-Pugh class, α-fetoprotein, and TNM stage as independent predictors of overall survival (all P<0.05). Antiviral agent type (LAM vs ETV) did not influence overall survival (median 9.6 months in LAM vs 13.6 months in ETV group; P=0.493). HCC treatment was not interrupted due to HBV flare up in any patient. CONCLUSIONS: The antiviral efficacy of LAM and ETV was similar and the type of antiviral agent did not influence overall survival in patients with HBV-related advanced HCC. Thus, LAM, which is less expensive than ETV in Korea, might be sufficient to control HBV in these patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antiviral Agents | - |
dc.subject.MESH | Carcinoma, Hepatocellular/blood | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/virology | - |
dc.subject.MESH | Chi-Square Distribution | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Drug Resistance, Viral/genetics | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Guanine/analogs & derivatives* | - |
dc.subject.MESH | Guanine/therapeutic use | - |
dc.subject.MESH | Hepatitis B e Antigens/blood | - |
dc.subject.MESH | Hepatitis B virus/genetics | - |
dc.subject.MESH | Hepatitis B virus/immunology | - |
dc.subject.MESH | Hepatitis B, Chronic/complications | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Lamivudine/therapeutic use* | - |
dc.subject.MESH | Liver Neoplasms/blood | - |
dc.subject.MESH | Liver Neoplasms/pathology* | - |
dc.subject.MESH | Liver Neoplasms/virology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.subject.MESH | alpha-Fetoproteins/metabolism | - |
dc.title | Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hye Sun Shin | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Chae Yoon Chon | - |
dc.contributor.googleauthor | OidovBaatarkhuu | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.identifier.doi | 10.1111/j.1440-1746.2012.07145.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02182 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A03544 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 22497450 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2012.07145.x/abstract | - |
dc.subject.keyword | efficacy | - |
dc.subject.keyword | entecavir | - |
dc.subject.keyword | hepatitis B virus hepatocellular carcinoma | - |
dc.subject.keyword | lamivudine | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Shin, Hye Sun | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Chon, Chae Yoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Shin, Hye Sun | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Chon, Chae Yoon | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.citation.volume | 27 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1528 | - |
dc.citation.endPage | 1534 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.27(9) : 1528-1534, 2012 | - |
dc.identifier.rimsid | 33554 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.